Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06996652 · ClinicalTrials.gov registry record · Phase 2
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
A Phase 2 study, sponsored by Yale University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT06996652 is a Phase 2 study that has not yet begun recruiting, run by Yale University. The registered enrollment target is 108 participants.
The verdict
NCT06996652, a Phase 2 study, has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
This is a phase 2 study to assess the ability of adalimumab as compared to placebo to reduce or prevent progression of synuclein-related neurodegeneration in persons with idiopathic REM Sleep Behavior Disorder (RBD). The Primary Endpoint will be change from baseline in expression of the Parkinson Disease Related Pattern (PDRP) will be assessed using change in 18-flurodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging.
Interventions
- DRUG Placebo
- DRUG Adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2026-06-29 |
| Est. Completion | 2029-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06996652
The ClinicalTrials.gov registry entry for NCT06996652 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06996652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06996652 about?
NCT06996652 is a clinical study titled "An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)". This is a phase 2 study to assess the ability of adalimumab as compared to placebo to reduce or prevent progression of synuclein-related neurodegeneration in persons with idiopathic REM Sleep Behavior Disorder (RBD). The Primary Endpoint will be change from baseline in expression of the Parkinson Di...
What is the current status of trial NCT06996652?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2026-06-29. Estimated completion is 2029-08-01.
What interventions are being tested in trial NCT06996652?
The interventions under investigation include: Placebo (DRUG), Adalimumab (DRUG).
Who is sponsoring clinical trial NCT06996652?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.